Search

Anhedonia, the loss of pleasure or motivation to engage in previously enjoyable activities, is associated with significant clinical impairment. Importantly, anhedonia is implicated in several different psychiatric disorders, presenting a promising opportunity for transdiagnostic treatment. In spite of its clinical significance, anhedonia is typically overlooked as a primary treatment target. Consequently, developing targeted treatments for anhedonia is of critical importance for population mental health. The present study aims to address this critical need by clarifying network-level neural dysfunction in a transdiagnostic anhedonia sample, with the long-term goal of identifying potential treatment targets.